NO20072632L - Oksadiazolderivater som DGAT-inhibitorer - Google Patents

Oksadiazolderivater som DGAT-inhibitorer

Info

Publication number
NO20072632L
NO20072632L NO20072632A NO20072632A NO20072632L NO 20072632 L NO20072632 L NO 20072632L NO 20072632 A NO20072632 A NO 20072632A NO 20072632 A NO20072632 A NO 20072632A NO 20072632 L NO20072632 L NO 20072632L
Authority
NO
Norway
Prior art keywords
optionally substituted
oxadiazole derivatives
dgat inhibitors
compounds
dgat
Prior art date
Application number
NO20072632A
Other languages
English (en)
Inventor
Thorsten Nowak
Alan Martin Birch
William Mccoull
Alleyn Plowright
Suzanne Saxon Bowker
Roger John Butlin
Craig Samuel Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35999598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072632(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0427328A external-priority patent/GB0427328D0/en
Priority claimed from GB0507403A external-priority patent/GB0507403D0/en
Priority claimed from GB0520383A external-priority patent/GB0520383D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20072632L publication Critical patent/NO20072632L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)

Abstract

Det er beskrevet forbindelser med formel (I) og salter og prodrug-forbindelser derav: hvor for eksempel R1 er eventuelt substituert aryl eller heteroaryl; Y er en bindingsgruppe valgt fra, for eksempel en direkte binding og en (substituert) alkylkjede; R2 er en eventuelt substituert aryl, en eventuelt substituert cykloalkyl eller en eventuelt substituert heterocyklisk gruppe. Prosesser for å lage slike forbindelser og anvendelse av dem som DGAT-inhibitorer, for eksempel ved behandling av fedme, er også beskrevet.
NO20072632A 2004-12-14 2007-05-24 Oksadiazolderivater som DGAT-inhibitorer NO20072632L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0427328A GB0427328D0 (en) 2004-12-14 2004-12-14 Chemical compounds
GB0507403A GB0507403D0 (en) 2005-04-13 2005-04-13 Chemical compounds
GB0520383A GB0520383D0 (en) 2005-10-07 2005-10-07 Chemical compounds
PCT/GB2005/004726 WO2006064189A1 (en) 2004-12-14 2005-12-09 Oxadiazole derivatives as dgat inhibitors

Publications (1)

Publication Number Publication Date
NO20072632L true NO20072632L (no) 2007-08-31

Family

ID=35999598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072632A NO20072632L (no) 2004-12-14 2007-05-24 Oksadiazolderivater som DGAT-inhibitorer

Country Status (15)

Country Link
US (2) US7795283B2 (no)
EP (1) EP1833806A1 (no)
JP (1) JP2008523133A (no)
KR (1) KR20070087096A (no)
AR (1) AR051842A1 (no)
AU (2) AU2005315430B2 (no)
BR (1) BRPI0519058A2 (no)
CA (1) CA2588162A1 (no)
IL (1) IL183279A0 (no)
MX (1) MX2007007101A (no)
NO (1) NO20072632L (no)
NZ (2) NZ587106A (no)
SA (1) SA05260407B1 (no)
TW (1) TW200633991A (no)
WO (1) WO2006064189A1 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
BRPI0519058A2 (pt) * 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006113919A2 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CN101460470B (zh) * 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
MX2008015228A (es) * 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
WO2007141502A1 (en) * 2006-06-06 2007-12-13 Astrazeneca Ab Chemical compounds
WO2007141517A1 (en) * 2006-06-08 2007-12-13 Astrazeneca Ab Benzimidazoles and their use for the treatemnt of diabetes
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
ES2397661T3 (es) 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Composiciones y sus usos dirigidos a la diacilglicerol aciltransferasa 1
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
CA2673076A1 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane carboxylates
WO2008099221A1 (en) * 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) * 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
EP2152271B1 (en) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5464709B2 (ja) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
ES2536406T3 (es) 2007-06-08 2015-05-25 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
CA2695434A1 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Chemical compounds 979
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
PE20100083A1 (es) * 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
KR101124821B1 (ko) * 2008-08-27 2012-03-26 에스케이 텔레콤주식회사 Ｉｍｓ 서비스를 위한 ｐ-ｃｓｃｆ 설정 시스템 및 ｉｍｓ 서비스를 위한 ｐ-ｃｓｃｆ 설정 방법
EP3025727A1 (en) * 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US20110224136A1 (en) * 2008-11-19 2011-09-15 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20110102910A (ko) 2008-12-19 2011-09-19 아스트라제네카 아베 1,3,4-옥사디아졸 유도체 및 당뇨병의 치료를 위한 이의 용도
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
EP2423182A4 (en) 2009-04-21 2012-11-07 Astellas Pharma Inc DIACYLETHYLENEDIAMINE COMPOUND
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
US8518969B2 (en) 2010-06-17 2013-08-27 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
WO2012044567A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
JP5868418B2 (ja) 2010-12-01 2016-02-24 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｃｒ２の４−置換シクロヘキシルアミノ−４−ピペリジニル−アセトアミドアンタゴニスト
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP6099753B2 (ja) * 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
CN108658889B (zh) * 2018-05-11 2021-12-17 贵州医科大学 一种含萘环的1,2,4-噁二唑-芳基哌嗪型化合物及其制法和用途
JP7410781B2 (ja) * 2019-07-17 2024-01-10 信越化学工業株式会社 ジメチルシクロブタノン化合物、ジメチルシクロブタン化合物及びそれらの製造方法
JP7335849B2 (ja) * 2019-07-17 2023-08-30 信越化学工業株式会社 ジメチルシクロブタン環を有するジエステル化合物及びその製造方法、並びにそれから誘導されるジメチルシクロブタン化合物の製造方法
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
JP2022547882A (ja) * 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983731A (en) 1989-03-17 1991-01-08 Nebraska Department Of Economic Development Separation and purification of sugar esters
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2000058491A1 (en) 1999-03-25 2000-10-05 The Kitasato Institute Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CA2369967A1 (en) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
DE10223273A1 (de) 2002-05-24 2003-12-04 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
WO2008011131A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
MXPA05000053A (es) 2002-07-12 2005-04-08 Aventis Pharma Gmbh Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
WO2005046670A1 (en) 2003-11-11 2005-05-26 The Skinny Drink Company Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) * 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
AU2006210056A1 (en) 2005-02-07 2006-08-10 F. Hoffmann-La Roche Ag Inhibitors of diacylglycerol acyltransferase (DGAT)
WO2006113919A2 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
JP2008540485A (ja) 2005-05-10 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ジアシルグリセロールアシルトランスフェラーゼ阻害剤
AU2006258917A1 (en) 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
CA2617055A1 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
KR20080063865A (ko) 2005-11-28 2008-07-07 에프. 호프만-라 로슈 아게 다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
WO2007137103A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
CN101460470B (zh) * 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
MX2008015228A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
WO2007141502A1 (en) 2006-06-06 2007-12-13 Astrazeneca Ab Chemical compounds
WO2007141517A1 (en) 2006-06-08 2007-12-13 Astrazeneca Ab Benzimidazoles and their use for the treatemnt of diabetes
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
US20120065196A1 (en) 2006-07-21 2012-03-15 Shuji Kitamura Amide compounds
US7569590B2 (en) 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR101107896B1 (ko) 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
CN101636155A (zh) 2006-11-29 2010-01-27 艾博特公司 二酰甘油o-酰基转移酶1型酶的抑制剂
WO2008099221A1 (en) 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
KR20100019470A (ko) 2007-04-30 2010-02-18 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
BRPI0811947A2 (pt) 2007-05-22 2014-11-11 Via Pharmaceuticals Inc Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP5464709B2 (ja) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2152271B1 (en) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
ES2536406T3 (es) 2007-06-08 2015-05-25 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CA2695434A1 (en) 2007-08-17 2009-02-26 Astrazeneca Ab Chemical compounds 979
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009071483A1 (en) 2007-12-07 2009-06-11 Via Pharmaceuticals, Inc. 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
KR20110102910A (ko) * 2008-12-19 2011-09-19 아스트라제네카 아베 1,3,4-옥사디아졸 유도체 및 당뇨병의 치료를 위한 이의 용도

Also Published As

Publication number Publication date
US20080096874A1 (en) 2008-04-24
EP1833806A1 (en) 2007-09-19
US7795283B2 (en) 2010-09-14
CA2588162A1 (en) 2006-06-22
AU2005315430A1 (en) 2006-06-22
KR20070087096A (ko) 2007-08-27
NZ587106A (en) 2012-03-30
JP2008523133A (ja) 2008-07-03
IL183279A0 (en) 2007-09-20
MX2007007101A (es) 2007-08-21
AR051842A1 (es) 2007-02-14
WO2006064189A1 (en) 2006-06-22
BRPI0519058A2 (pt) 2008-12-23
NZ555683A (en) 2010-09-30
US20100317653A1 (en) 2010-12-16
TW200633991A (en) 2006-10-01
AU2005315430B2 (en) 2010-05-27
SA05260407B1 (ar) 2009-11-15
AU2010206031A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
NO20072632L (no) Oksadiazolderivater som DGAT-inhibitorer
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20076006L (no) Acetylenderivater
NO20073720L (no) Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer
NO20075809L (no) DNA-PK inhibitorer
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20063446L (no) Tiazolderivater
NO20085107L (no) Spirosykliske nitriler som proteaseinhibitorer
WO2009016462A3 (en) Substituted bicyclolactam compounds
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
WO2008114817A1 (ja) 新規なアデニン化合物
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20070368L (no) Virale polymeraseinhibitorer
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
NO20073572L (no) Nye forbindelser
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20055688L (no) Organiske forbindelser
TW200640862A (en) Pyridyl acetic acid compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application